CELL INTELLIGENCE · 肿瘤细胞治疗研究

BACKGROUND AND OBJECTIVE: S1PR1 (sphingosine-1-phosphate receptor 1) plays a critical role in key cancer-related processes such as cell migration, proliferation, and survival. While its functions are well-established in the cardiovascular and immune systems, its mechanism in cancer remains unclear. Our study aims to investigate the expression, mutations, post-translational modifications, and immune infiltration of S1PR1 across different cancers, and particularly focus on its potential as a therapeutic target and prognostic biomarker. METHODS: We utilized HPA, GTEx, TCGA and CPTAC bioinformation databases to evaluate the expression level of S1PR1 between normal and cancer tissue. Sequence conservation and phylogenetic analysis of S1PR1 are assessed by NCBI and Pfam database. Gene mutations, methylation, phosphorylation, and immune infiltration of S1PR1 were analyzed by cBioPortal, MethSuv, CPTAC and TIMER2.0 respectively. RESULTS: S1PR1 expression varied significantly among cancers, with decreased levels in bladder and breast cancers, and increased levels in renal cell carcinoma, thyroid cancer, and acute myeloid leukemia. Mutation analysis revealed frequent mutations in endometrial, lung, and ovarian cancers. Reduced methylation in lung adenocarcinoma correlated with improved survival. Elevated phosphorylation was observed in glioblastoma and renal carcinoma. Immune infiltration analysis showed significant correlations with CAFs and γδ T cells. CONCLUSION: S1PR1 plays a critical role in cancer progression through its expression, mutations, and modifications. These findings suggest that S1PR1 could be served as a potential biomarker and therapeutic target in cancer, but it need a further validation in clinical settings is warranted.